Work

A Phase 2 Study of Actinium-225 (225Ac)-lintuzumab in Older Patients with Untreated Acute Myeloid Leukemia (AML)

Year: 2019

Type: article

Source: Journal of medical imaging and radiation sciences

DOI: 10.1016/j.jmir.2019.03.113

Authors: Ehab Atallah, Mark Berger, Joseph Jurcic, Gail Roboz, William Tse, Raya Mawad, David Rizzieri, Kebede Begna, Johnnie Orozco, Michael Craig, Moshe Yair Levy, Laura Finn, Khan Sharif, Alexander Perl, Jae Park

Institutions: Medical College of Wisconsin, Actinium Pharmaceuticals (United States), Columbia University Irving Medical Center, Cornell University, Weill Cornell Medicine, University of Louisville, Duke University, Mayo Clinic, Fred Hutch Cancer Center, West Virginia University, Baylor University Medical Center, Ochsner Medical Center, University of Pennsylvania, Memorial Sloan Kettering Cancer Center

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2935634911

FWCI: 2.121

Cites:

Cited by: 23

Related to: 10